Search

for
Search:

Research

5 / 1000+ results

research Case of de novo nail psoriasis triggered by the second dose of Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine

28 citations , September 2021 in “JAAD Case Reports”

This study reports that the Pfizer-BioNTech COVID-19 vaccine showed 52% protection against COVID-19 after the first dose and 95% after the second in phase 3 trials.

research A case of extensive alopecia areata following Pfizer‐BioNTech BNT162b2 mRNA COVID‐19 vaccine with favorable outcome

9 citations , January 2023 in “Journal of Cutaneous Immunology and Allergy”

This case report describes a 37-year-old woman who developed widespread hair loss following the BNT162b2 mRNA vaccine, which mostly recovered after topical corticosteroid treatment.

research Alopecia Areata after COVID-19 Vaccines

3 citations , January 2023 in “Skin appendage disorders”

This study reported five cases of alopecia areata following COVID-19 vaccination, with one patient experiencing worsening symptoms with each vaccine booster.

research A Case Series and Literature Review of Telogen Effluvium and Alopecia Universalis after the Administration of a Heterologous COVID-19 Vaccine Scheme

2 citations , February 2023 in “Vaccines”

This study reported cases of post-vaccine telogen effluvium and alopecia among five individuals in Ecuador following a mixed COVID-19 vaccination regimen, typically appearing within 3 to 17 days after inoculation.

research Medication-induced hair loss: An update

1 citations , September 2023 in “Journal of the American Academy of Dermatology”

COVID-19 vaccines have been linked to an increase in hair loss conditions.

View more "pfizer biontech" in research →

Community Join

4 / 1000+ results

community An arthritis drug that can be used for Alopecia.

5 upvotes 4 years ago

An arthritis drug, baricitinib, is discussed as a potential treatment for autoimmune alopecia, not androgenetic alopecia. Ritlecitinib is also mentioned as a possible treatment for scarring alopecia.

community PP405 Update and My Take on Pelage

in Research/Science 86 upvotes 11 months ago

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

community [Theory] Big Bald is deliberately delaying the cure indefinitely

348 upvotes 1 year ago

The conversation humorously suggests that the hair loss industry, referred to as "Big Bald," deliberately delays a cure to profit from ongoing treatments like minoxidil, finasteride, and dutasteride. Participants debate whether a cure would be more profitable than current treatments, with some suggesting that the industry prefers continuous treatments for sustained profit.

community PYRILUTAMIDE PHASE 3 RESULTS : No statistical significance

124 upvotes 2 years ago

The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.

View more "pfizer biontech" in community →